Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy.

"atomic coordinates and structure factors have been deposited in the protein data bank under the accession code 8ivu."

"Competing Interests: H.S.K. is the founder and chief scientific officer of Checkmate Therapeutics Inc. H.S.K. and H.J. are shareholders of Checkmate Therapeutics Inc. The authors have no competing or financial conflicts of interest to declare."

"This work was supported by the Korea Health Technology R&D project through the Korea Health Industry Development Institute (HI14C1324), the National Research Foundation of Korea (NRF) grants funded by the Korean Government (MSIT) (2023R1A2C2003586, 2020R1A2C3007792, 2022R1A2B5B03001199, 2022R1A5A102641311, 2022R1A2C3006924, 2013M3A9D5072551, 2018R1A5A2025079 and 2022M3E5E8018388) and the “Team Science Award” of Yonsei University College of Medicine (6-2021-0194). We thank the staff of the beamlines at the Pohang Light Source (Republic of Korea) for their help with data collection."